TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12351592

Group type: EXPERIMENTAL
Intervention: Antimicrobial lozenge (Bacitracin, Clotrimazole, Gentamicin)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 137
Study: 10399232

Group type: EXPERIMENTAL
Intervention: Structum and ibuprofen (1200 mg/day) for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ibuprofen only
Number of subjects: 100
Study: 7480566

Group type: EXPERIMENTAL
Intervention: Labetalol (nonselective adrenoceptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 1979499

Group type: EXPERIMENTAL
Intervention: Dopaminergic antidepressant drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (gonadotropins, testosterone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DA agonist and/or 5‐HT antagonist drugs
Number of subjects: 0
Study: 6280229

Group type: EXPERIMENTAL
Intervention: KMT with polychemotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: KMT with radiotherapy
Number of subjects: 38
Study: 30835152

Group type: EXPERIMENTAL
Intervention: Adjunctive tianeptine 37.5 mg/day
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 28634889

Group type: EXPERIMENTAL
Intervention: Airflow
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Seat vibration
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined airflow and vibration
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study: 25154734

Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser treatment (three monthly treatments)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study: 22560940

Group type: EXPERIMENTAL
Intervention: Animal protein diet
Number of subjects: 11116

Group type: EXPERIMENTAL
Intervention: Animal protein diet among ever smokers
Number of subjects: 11116
Study: 21117975

Group type: EXPERIMENTAL
Intervention: Violent video game
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Violent video game (females)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Violent video game (males)
Number of subjects: 0
Study: 19724023

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) plus Orlistat (120 mg, 3 times a day with meals)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) plus Rimonabant (20 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ezetimibe plus Orlistat
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ezetimibe plus Rimonabant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 30
Study: 17634977

Group type: EXPERIMENTAL
Intervention: Five asymptotic interval estimators for the proportion ratio (PR) including WLS estimator, Mantel-Haenszel type weight, Fieller's Theorem with WLS optimal weight, Fieller's Theorem with randomization-based optimal weight, and stratified two-sample proportion test with optimal weight.
Number of subjects: 0
Study: 15631659

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/day) or Stanazol (6 mg/day) and ATRA (10 mg/day) for at least 3 months
Number of subjects: 55
Study: 11531038

Group type: EXPERIMENTAL
Intervention: Aerobic training programme (13 weeks, twice a week, 1 hour per session)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 33
Study: 9603640

Group type: EXPERIMENTAL
Intervention: EPx4 cycles (etoposide 120 mg/m2 i.v. days 1-3 and cisplatin 80 mg/m2 day 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: EPx6 cycles (etoposide 120 mg/m2 i.v. days 1-3 and cisplatin 80 mg/m2 day 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EPx4 cycles
Number of subjects: 70
Study: 7825195

Group type: EXPERIMENTAL
Intervention: Suicide intervention classes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3420161

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg 3 times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (drug-free)
Number of subjects: 10
Study: 30296633

Group type: EXPERIMENTAL
Intervention: Involuntary treatment
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Non-consensual care
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Physical restraints
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Dependency for activities of daily life
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Informal caregiver burden
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Aging
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Requests for involuntary treatment
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Application of involuntary treatment
Number of subjects: 1194
Study: 27263325

Group type: EXPERIMENTAL
Intervention: SRP + MM
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study: 24811759

Group type: EXPERIMENTAL
Intervention: Initial invitation by mail
Number of subjects: 3777

Group type: EXPERIMENTAL
Intervention: Initial invitation by phone
Number of subjects: 3777

Group type: EXPERIMENTAL
Intervention: Recall by appointment with a specialist practitioner
Number of subjects: 3777

Group type: COMPARATOR
Intervention: Mail recall
Number of subjects: 3777

Group type: COMPARATOR
Intervention: Face-to-face counselling with GP
Number of subjects: 3777
Study: 21948957

Group type: EXPERIMENTAL
Intervention: APT Hotline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APT Pharmacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine PN
Number of subjects: 0
Study: 20103545

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg at 90 minutes preoperatively and 150 mg at 12 and 24 hours postoperatively)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 40
Study: 18211256

Group type: EXPERIMENTAL
Intervention: Obstetric gel use
Number of subjects: 251

Group type: COMPARATOR
Intervention: No obstetric gel use (Control)
Number of subjects: 251
Study: 17507385

Group type: EXPERIMENTAL
Intervention: Closed speculum group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open speculum group
Number of subjects: 45
Study: 12860574

Group type: EXPERIMENTAL
Intervention: Fatigued respondents (n=3528)
Number of subjects: 7162

Group type: COMPARATOR
Intervention: Nonfatigued respondents (n=3634)
Number of subjects: 7162

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 7162

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 7162
Study: 10852317

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2649
Study: 9356796

Group type: EXPERIMENTAL
Intervention: clemastine fumarate
Number of subjects: 403

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 403
Study: 8402658

Group type: EXPERIMENTAL
Intervention: 4‐HPR 200 mg/daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 60
Study: 2876722

Group type: EXPERIMENTAL
Intervention: Bisoprolol (2.5-40 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propranolol (40 and 80 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Atenolol (50 and 100 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metoprolol (50 and 100 mg)
Number of subjects: 36
Study: 29320670

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: E-cigarettes consideration
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Spirometry testing
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Diagnosis of COPD
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Misdiagnosis of COPD
Number of subjects: 1050
Study: 26994397

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for ultra-high risk (CBTuhr)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 196
Study: 26859020

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 22116378

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride (10 mg) combined with virtual reality exposure therapy (VRET)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo combined with virtual reality exposure therapy (VRET)
Number of subjects: 67
Study: 20181126

Group type: EXPERIMENTAL
Intervention: Infrequent modified images (p = .2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequent unmodified images (p = .8)
Number of subjects: 0
Study: 18640889

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) such as anastrozole or letrozole for 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential approach of tamoxifen for 2-3 years followed by anastrozole or exemestane for 2-3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole for up to 4-5 years after completing 5 years of tamoxifen in node-positive disease
Number of subjects: 0
Study: 15875763

Group type: EXPERIMENTAL
Intervention: Cephalometric analysis of soft tissues
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional dental evaluations
Number of subjects: 33
Study: 12861539

Group type: EXPERIMENTAL
Intervention: In-line projection screen
Number of subjects: 108

Group type: COMPARATOR
Intervention: Overhead monitor
Number of subjects: 108
Study: 10100179

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive preparation (20 micrograms of ethinyl estradiol plus 0.15 mg desogestrel)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Perimenopausal OC-treated women
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (healthy, normally menstruating women)
Number of subjects: 3
Study: 8684872

Group type: EXPERIMENTAL
Intervention: PFP-2 vaccine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline vaccine (control)
Number of subjects: 34
Study: 1516602

Group type: EXPERIMENTAL
Intervention: Defibrotide 400 mg b.d. for 30 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6408669

Group type: EXPERIMENTAL
Intervention: Desipramine (150‐350 mg/day)
Number of subjects: 40
Study: 31792291

Group type: EXPERIMENTAL
Intervention: Microbolus technique (MBT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard CTA protocol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fixed-bolus delay protocol
Number of subjects: 70
Study: 30001195

Group type: EXPERIMENTAL
Intervention: Combination of extra-amniotic Foley's catheter inflated by 30 cm3 of normal saline and 25 micrograms of vaginal misoprostol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Vaginal misoprostol alone (25 micrograms)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of extra-amniotic Foley's catheter and vaginal misoprostol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Vaginal misoprostol alone
Number of subjects: 180
Study: 27825326

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) program (two 90-min lessons with a 1-week interval)
Number of subjects: 37
Study: 24845183

Group type: EXPERIMENTAL
Intervention: Cold water immersion (1 °C) during SECPT
Number of subjects: 61

Group type: COMPARATOR
Intervention: Room temperature water immersion (20 °C) during SECPT
Number of subjects: 61
Study: 22677755

Group type: EXPERIMENTAL
Intervention: Mexidol (antioxidant)
Number of subjects: 98
Study: 20164320

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 20-40 g in 300 mL water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 10-40 g in 300 mL water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whey Protein Hydrolysate (WPH) 10 g in 300 mL water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) > or = 10 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whey Protein Hydrolysate (WPH) 10 g
Number of subjects: 0
Study: 18029338

Group type: EXPERIMENTAL
Intervention: NeOpuntia
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 16007036

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12525910

Group type: EXPERIMENTAL
Intervention: Excision and marsupialization technique (Group 1, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sinus excision technique (Group 2, n=20)
Number of subjects: 40
Study: 9797756

Group type: EXPERIMENTAL
Intervention: Air during exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: 35% oxygen during exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Induced hypoxaemia at rest (titrated mixture of air and oxygen)
Number of subjects: 20
Study: 7659385

Group type: EXPERIMENTAL
Intervention: 123I-BMIPP
Number of subjects: 9

Group type: COMPARATOR
Intervention: 201Tl
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BMIPP
Number of subjects: 9
Study: 2799651

Group type: EXPERIMENTAL
Intervention: 1 gm cefazolin intramuscularly before surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 gm cefazolin in buttock fat, buttock muscle, or by intravenous injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 gm cefazolin intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 gm cefazolin intravenously
Number of subjects: 0
Study: 1095040

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg diazepam
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg diazepam
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg diazepam
Number of subjects: 34
Study: 31952882

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 831
Study: 30698272

Group type: EXPERIMENTAL
Intervention: ADAM zolmitriptan 3.8 mg
Number of subjects: 321
Study: 25605856

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 636
Study: 23371540

Group type: EXPERIMENTAL
Intervention: LipoNasal (LN)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Bepanthen (BP)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Rhinomer (RH)
Number of subjects: 92
Study: 21749017

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study: 19808140

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg) administered as a 30-minute intravenous infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Temsirolimus (25 mg) administered as a 30-minute intravenous infusion in patients receiving hemodialysis
Number of subjects: 13
Study: 16623314

Group type: EXPERIMENTAL
Intervention: In-person progress reports from the surgical liaison nurse (SLN)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Routine perioperative care
Number of subjects: 92
Study: 10579246

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 8678170

Group type: EXPERIMENTAL
Intervention: Naturalistic follow-up assessments at 6, 12, and 18 months
Number of subjects: 188
Study: 1763796

Group type: EXPERIMENTAL
Intervention: 50 micrograms of vaccine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 micrograms of vaccine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 micrograms of vaccine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 micrograms of vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 6130077

Group type: EXPERIMENTAL
Intervention: Buspirone (30, 60, and 90 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alpha-methyl-p-tyrosine and gamma-butyrolactone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 8
Study: 31289192

Group type: EXPERIMENTAL
Intervention: Parent and child depression symptoms
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Family chaos
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Emotional triggers of asthma
Number of subjects: 223
Study: 29231094

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily after 5 days of low-molecular-weight heparin)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Dalteparin (200 IU/kg once daily for 1 month followed by 150 IU/kg once daily)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 1050
Study: 27294991

Group type: EXPERIMENTAL
Intervention: Occupation-based intervention (n = 98)
Number of subjects: 217

Group type: COMPARATOR
Intervention: No intervention (Control group, n = 119)
Number of subjects: 217
Study: 24562789

Group type: COMPARATOR
Intervention: Tolterodine (cohort I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment (cohort II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distribution-based analysis (cohort I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distribution-based analysis (cohort II)
Number of subjects: 0
Study: 23197976

Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 inhibitor (vildagliptin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 20206803

Group type: EXPERIMENTAL
Intervention: EVAR using the Talent eLPS stent graft
Number of subjects: 166

Group type: COMPARATOR
Intervention: Open surgical AAA repair
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: EVAR using the Talent eLPS stent graft (5-year follow-up)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: CoilTrac delivery system (confirmatory group)
Number of subjects: 166
Study: 16806875

Group type: EXPERIMENTAL
Intervention: daily rhDNase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alternate day rhDNase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hypertonic saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16223001

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control
Number of subjects: 276
Study: 12084804

Group type: EXPERIMENTAL
Intervention: AAT once/week
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AAT three times/week
Number of subjects: 45

Group type: COMPARATOR
Intervention: No AAT
Number of subjects: 45
Study: 9871843

Group type: EXPERIMENTAL
Intervention: TRH (0.4 mg intravenous bolus)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8714022

Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous administration of oxytocin (OT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Continuous intravenous administration of oxytocin (OT)
Number of subjects: 106
Study: 2398244

Group type: EXPERIMENTAL
Intervention: 3% sodium tetradecyl sulphate (STS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: absolute alcohol (AA)
Number of subjects: 52
Study: 30947936

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 2754

Group type: COMPARATOR
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 2754
Study: 28625615

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 U
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1000 U
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Number of subjects: 105
Study: 27997954

Group type: EXPERIMENTAL
Intervention: Intensive Language Action Therapy (ILAT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Promoting Aphasic Communicative Effectiveness (PACE)
Number of subjects: 24
Study: 24389597

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20mg/day) for 30 days
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4mg/day) for 30 days
Number of subjects: 155
Study: 22353460

Group type: EXPERIMENTAL
Intervention: Philips Sonicare for Kids (SFK) A (low amplitude, 7°)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Philips Sonicare for Kids (SFK) B (high amplitude, 9°)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Oral‐B Stages 3 toothbrush (MTB)
Number of subjects: 68
Study: 20521319

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 32
Study: 17955096

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Lamotrigine with concomitant antipsychotics
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Lamotrigine with concomitant valproate, lithium, or antidepressants
Number of subjects: 1175
Study: 16274805

Group type: EXPERIMENTAL
Intervention: Lipid-based nose ointment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 33
Study: 12110024

Group type: EXPERIMENTAL
Intervention: Vitamin E-modified cellulose membrane (CL-E)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-flux cellulose acetate (CA)
Number of subjects: 8
Study: 10542930

Group type: EXPERIMENTAL
Intervention: At risk group (men with hyperlipidaemia)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (patients undergoing nasal surgery)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Subgroup with fasting lipids > 6.5 mmol/l
Number of subjects: 197
Study: 8998247

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 4736
Study: 1699888

Group type: EXPERIMENTAL
Intervention: 30 ml of 0.33% bupivacaine (20 ml 0.5% bupivacaine + 10 ml of N saline)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 20 ml of 0.5% bupivacaine + 10 ml of dextraven-150 (6% solution in 5% dextrose)
Number of subjects: 84